Managers

Fresh off Fastly's big IPO, August Capital targets 2020 fundraising

Valuations start to stabilize in H1 while market remains strong

Ex-Trinity Ventures GP Scholnick reportedly focusing on seed

Polychain collects over $174 mln for initial venture fund

Polychain Capital has raised over $174 million for its debut venture fund, according to an SEC filing. No target was listed in the document. Polychain invests in cryptocurrency protocols and companies.

Accion Venture Lab gathers $33 mln for new fund

Accion Venture Lab has raised $33 million for a new fund. The fund will invest in fintech startups. Launched in 2012, Accion Venture Lab is the seed-stage investment initiative of global nonprofit Accion.

Vensana wraps up inaugural medtech fund

Vensana Capital, which was launched by healthcare-focused venture firm Versant Ventures, has closed its debut fund at US$225 million. Vensana Capital I's limited partners include public pensions, university endowments, foundations, academic health systems, family offices and fund-of-funds. The fund will invest in the medical tech sector. Versant's offices include San Diego, San Francisco, Minneapolis, New York City and Vancouver, British Columbia.

VC-backed Bolt taps Schatzman as CEO

Redwood City, California-based Bolt Biotherapeutics, a biotech firm focused on treating cancer, has named Dr. Randall Schatzman as CEO and a member of the board of directors. Previously, he was CEO of Alder BioPharmaceuticals Inc. Bolt's backers included Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences.

United Kingdom sees the bulk of European VC activity in H1

The tranformation of venture capital forges a new role for GPs

The past decade brought unprecedented change to venture capital. Today’s GP must bring together the sometimes competing goals of specialization, diversification and capitalization

Xiang He Capital racks up $425 mln for fund

Xiang He Capital, a TMT-focused venture firm in China, has closed its second US-denominated fund at a hard cap of $425 million, beating its $350 million target. The fund's limited partners include global consultants, university endowments, foundations, family offices, pensions and fund-of-funds.